MY140903A - Imidazole derivatives used as tafia inhibitors - Google Patents

Imidazole derivatives used as tafia inhibitors

Info

Publication number
MY140903A
MY140903A MYPI20051748A MYPI20051748A MY140903A MY 140903 A MY140903 A MY 140903A MY PI20051748 A MYPI20051748 A MY PI20051748A MY PI20051748 A MYPI20051748 A MY PI20051748A MY 140903 A MY140903 A MY 140903A
Authority
MY
Malaysia
Prior art keywords
imidazole derivatives
derivatives used
tafia inhibitors
inhibitors
compounds
Prior art date
Application number
MYPI20051748A
Inventor
Christopher Dr Kallus
Holger Dr Heitsch
Andreas Dr Lindenschmidt
Sven Dr Grueneberg
Szillat Hauke
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY140903(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MY140903A publication Critical patent/MY140903A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

THE INVENTION RELATES TO COMPOUNDS OF THE FORMULA 1 , WHICH ARE INHIBITORS OF ACTIVATED THROMBIN-ACTIVALABLE FIBRINOLYSIS INHIBITOR. THE COMPOUNDS OF THE FORMULA 1 ARE SUITABLE FOR PRODUCING MEDICAMENTS FOR THE PROPHYLAXIS AND THERAPY OF DISORDERS ASSOCIATED WITH THROMBOSES, EMBOLISMS, HYPERCOAGULABILITY OR FIBROTIC CHANGES.
MYPI20051748A 2004-04-22 2005-04-20 Imidazole derivatives used as tafia inhibitors MY140903A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004020186A DE102004020186A1 (en) 2004-04-22 2004-04-22 Heterocyclyl acetic acids as inhibitors of TAFla

Publications (1)

Publication Number Publication Date
MY140903A true MY140903A (en) 2010-01-29

Family

ID=34964308

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20051748A MY140903A (en) 2004-04-22 2005-04-20 Imidazole derivatives used as tafia inhibitors

Country Status (35)

Country Link
EP (2) EP1864979B1 (en)
JP (1) JP4939401B2 (en)
KR (1) KR101162047B1 (en)
CN (1) CN100572376C (en)
AR (1) AR053302A1 (en)
AT (2) ATE386737T1 (en)
AU (1) AU2005238144B2 (en)
BR (1) BRPI0510159A (en)
CA (1) CA2563401C (en)
CR (1) CR8650A (en)
CY (1) CY1108087T1 (en)
DE (2) DE102004020186A1 (en)
DK (1) DK1740569T3 (en)
EC (1) ECSP066941A (en)
ES (1) ES2299026T3 (en)
HK (1) HK1101823A1 (en)
HR (1) HRP20080099T3 (en)
IL (1) IL178672A (en)
MA (1) MA28543B1 (en)
MY (1) MY140903A (en)
NI (1) NI200600217A (en)
NO (1) NO20065320L (en)
NZ (1) NZ550757A (en)
PE (1) PE20060172A1 (en)
PL (1) PL1740569T3 (en)
PT (1) PT1740569E (en)
RS (1) RS50553B (en)
RU (1) RU2375356C2 (en)
SI (1) SI1740569T1 (en)
TN (1) TNSN06341A1 (en)
TW (1) TWI359016B (en)
UA (1) UA87306C2 (en)
UY (1) UY28868A1 (en)
WO (1) WO2005105781A1 (en)
ZA (1) ZA200607668B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2537093T3 (en) 2006-12-06 2015-06-02 Sanofi Sulfamide derivatives used as TAFIa inhibitors
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
CA2678069A1 (en) * 2007-02-13 2008-08-21 Schering Corporation Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
BRPI0814294A2 (en) 2007-07-19 2015-02-03 Metabolex Inc N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders.
EP2262783A2 (en) * 2008-02-21 2010-12-22 Sanofi-Aventis Covalently binding imaging probes
JP5531011B2 (en) * 2008-06-06 2014-06-25 サノフイ Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa
CA2741783A1 (en) 2008-10-29 2010-05-06 Taisho Pharmaceutical Co., Ltd. Compounds having tafia inhibitory activity
RU2538506C2 (en) * 2009-05-15 2015-01-10 Санофи METHOD OF PRODUCING COMPOUND USED AS TAFIa INHIBITOR
FR2947266B1 (en) * 2009-06-26 2011-06-17 Servier Lab NOVEL 2-MERCAPTOCYCLOPENTANECARBOXYLIC ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
WO2011041154A1 (en) 2009-10-01 2011-04-07 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
DK2548871T3 (en) 2010-03-18 2017-11-06 Daiichi Sankyo Co Ltd CYCLOAL COOL SUBSTITUTED IMIDAZOLD DERIVATIVE
JP5778133B2 (en) * 2010-03-18 2015-09-16 第一三共株式会社 Cyclopropanecarboxylic acid derivative
SG189420A1 (en) 2010-11-11 2013-05-31 Sanofi Sa Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives
EP2782574B1 (en) 2011-11-25 2016-03-30 Sanofi Salt of (r) ethyl-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1h-imidazol-4-yl)-propanoate
US9102657B2 (en) * 2011-11-25 2015-08-11 Sanofi Sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid
EP2782575B1 (en) 2011-11-25 2016-04-20 Sanofi Crystalline salts of r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
MX2015016961A (en) * 2013-06-10 2016-04-25 Sanofi Sa Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals.
JPWO2017170460A1 (en) 2016-03-29 2019-02-07 第一三共株式会社 Inflammatory bowel disease treatment
CA3032432A1 (en) 2016-08-03 2018-02-08 Charles A. Mcwherter Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013526A1 (en) * 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
JP2005516972A (en) 2002-01-22 2005-06-09 ファイザー・インク 3- (imidazolyl) -2-aminopropionic acid used as TAFI-A inhibitor for the treatment of thrombotic diseases

Also Published As

Publication number Publication date
MA28543B1 (en) 2007-04-03
PT1740569E (en) 2008-03-31
RU2375356C2 (en) 2009-12-10
RS50553B (en) 2010-05-07
UY28868A1 (en) 2005-11-30
EP1740569A1 (en) 2007-01-10
ZA200607668B (en) 2008-03-26
RU2006141246A (en) 2008-06-10
ATE523505T1 (en) 2011-09-15
NZ550757A (en) 2010-06-25
CY1108087T1 (en) 2014-02-12
ES2299026T3 (en) 2008-05-16
ATE386737T1 (en) 2008-03-15
KR101162047B1 (en) 2012-07-04
EP1740569B1 (en) 2008-02-20
TWI359016B (en) 2012-03-01
AU2005238144B2 (en) 2010-08-26
SI1740569T1 (en) 2008-06-30
IL178672A0 (en) 2007-02-11
AU2005238144A1 (en) 2005-11-10
CA2563401C (en) 2012-08-07
DK1740569T3 (en) 2008-06-02
CR8650A (en) 2007-12-04
CA2563401A1 (en) 2005-11-10
ECSP066941A (en) 2006-12-20
PE20060172A1 (en) 2006-03-31
IL178672A (en) 2011-08-31
DE502005002927D1 (en) 2008-04-03
HK1101823A1 (en) 2007-10-26
UA87306C2 (en) 2009-07-10
JP4939401B2 (en) 2012-05-23
TNSN06341A1 (en) 2008-02-22
CN1950357A (en) 2007-04-18
KR20070007346A (en) 2007-01-15
PL1740569T3 (en) 2008-07-31
NO20065320L (en) 2007-01-12
NI200600217A (en) 2008-06-17
DE102004020186A1 (en) 2005-11-17
TW200602325A (en) 2006-01-16
EP1864979B1 (en) 2011-09-07
BRPI0510159A (en) 2007-10-02
AR053302A1 (en) 2007-05-02
WO2005105781A1 (en) 2005-11-10
CN100572376C (en) 2009-12-23
EP1864979A1 (en) 2007-12-12
JP2007533672A (en) 2007-11-22
HRP20080099T3 (en) 2008-03-31

Similar Documents

Publication Publication Date Title
MY140903A (en) Imidazole derivatives used as tafia inhibitors
PT1940839E (en) Pyridopyrimidinone inhibitors of pi3kalpha
HK1119699A1 (en) Pyridopyrimidinone inhibitors of pi3kalpha
UA83875C2 (en) Quinoline derivatives for use as mycobacterial inhibitors
WO2008033562A3 (en) Kinase inhibitor compounds
WO2009011850A3 (en) Novel therapeutic compounds
WO2009126863A3 (en) Pyridyl inhibitors of hedgehog signalling
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2009006195A (en) 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use.
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
GB2466912A (en) Compositions and methods for treating lysosomal disorders
UA104002C2 (en) Normal;heading 1;heading 2;heading 3;MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA
MX2009010960A (en) Heterocyclic compounds and their methods of use.
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
TW200700064A (en) Novel compounds
WO2010033701A3 (en) Inhibitors of sphingosine kinase 1
IL195217A0 (en) Protein kinase inhibitors and uses thereof
UA85505C2 (en) Kinase inhibitors
WO2006028963A3 (en) Substituted heterocyclic compounds and uses thereof
NO20082096L (en) Azaindole-2-karboksamidderivativer
ATE542800T1 (en) KINASE INHIBITORS AND THEIR METHODS OF APPLICATION
WO2010021934A3 (en) Azaindole inhibitors of iap
MX2021001471A (en) Substituted benzimidazoles as pad4 inhibitors.